Australasian Psoriasis Registry
What is the APR?
The Australasian Psoriasis Registry (APR) is an online database that collects valid and reliable clinical data on people with psoriasis in Australia and New Zealand. The Project, led by the Skin & Cancer Foundation Inc, ultimately aims to transform the way patients with psoriasis are managed.
The APR brings together key information about people with psoriasis, including the type of treatments they are undergoing, when they were diagnosed, and whether they have any co-morbidities. Our aim is to provide new insights into treatment responses, and to understand more about patient health status and their quality of life.
The APR also aims to provide reliable and valid data for Australian doctors, medical researchers, consumers, policy makers, drug development companies, and approval agencies.
How does it work?
By collecting long-term information about patient's psoriasis management, health status, and quality of life, the Apr can provide reliable and valid outcome data.
The APR also focuses on the long-term safety and efficacy of established and new generation 'biologic' drugs, and the impact of living with psoriasis.
News from the APR
The APR is now providing valuable research data about people with psoriasis in Australia.
Since data was first collected for the APR in 2008, over 1,500 psoriasis patients have been recruited. Of these patients, 37.1% are female and 62.9% are male. The median age for all patients is 50.8 years.
The APR has revealed there is a substantial difference in the initial diagnosis of psoriasis for men and women in Australia. It appears males are diagnosed with psoriasis almost five years later than females (median age at diagnosis was 24.7 years for males and 20 years for females).
Co-morbidities of psoriasis patients
Recently, data from the APR has also provided further evidence about the link between psoriasis and other diseases and conditions.
Each patient on the APR has an average of 2.1 co-morbidities. A significant result given the importance of co-morbidities in psoriasis patients. Less than a quarter of patients on the registry have no recorded co-morbidity.
Obesity is by far the most common co-morbidity in the APR
patients, with over 50% of patients being obese. A further 35.7% of patients are
Other co-morbidities recorded in male and female psoriasis patients on the APR included:
- Depression - 16.4% of patients
- Hypertension - 23.6% of patients
- Hyperlipidaemia (abnormally high levels of fats, such as triglycerides or cholesterol, in the blood) - 19.8% of patients
- Diabetes - 11.3% of patients
- Non-melanoma skin cancer - 9.4% of patients
- Liver disease - 8.2% of patients
Joining the APR
We are always looking for new hospitals and dermatology practices to contribute patient data into the APR. You will help us to learn more about psoriasis in Australia and New Zealand and, ultimately, improve patient care and the quality of life for people with psoriasis.
Australian healthcare professionals can learn more about the APR, including how their patients' data is collected, by calling (03) 9623 9451.
The APR will assist dermatology practices in Australia and New Zealand with entering and updating data.
If you would like to arrange to have someone come to your site to demonstrate how the APR will collect your patients' data, and to help train users on data entry into the Registry, please contact Simon Cumming on (03) 9623 9451, or by email at email@example.com